More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

New patent secured in US for non-cancer applications

Oct 9, 2017 at 9:38 PM EDT · Issued by Neurizon Therapeutics Limited

Filed with ASX · Oct 9, 2017 at 9:38 PM EDT

On 6ix: 6ix.com/news/new-patent-secured-in-us-for-non-cancer-applications

Neurizon Therapeutics Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Neurizon Therapeutics Limited on 6ix

Story so far

  • PharmAust secures core Europe patentSep 12, 2017
  • New European patent granted for non-cancer applicationsJun 8, 2017
  • PharmAust secures core patent in JapanJun 6, 2017

Earlier from Neurizon Therapeutics

  • Reformulation project achieves first milestones and on-trackSep 19, 2017
  • PharmAust secures core Europe patentSep 11, 2017
  • PharmAust & Nihon Nohyaku Japan Enter Assignment AgreementSep 3, 2017
  • Appendix 4E & Full Year Statutory Accounts 2017Aug 31, 2017
  • PharmAust Shareholders UpdateAug 21, 2017

Later from Neurizon Therapeutics

  • Monepantel reformulation project continues to progressOct 16, 2017
  • Appendix 4C - Quarterly Report & Brief Company UpdateOct 26, 2017
  • Epichem Update - progress on milestones and revenue targetsOct 31, 2017
  • New drugs patented for cancer in USANov 15, 2017
  • New MPL analogues show greater anti-cancer activityNov 22, 2017
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer